One of these antigens is mesothelin (MSLN), which is a glycoprotein overexpressed in mesothelioma, ovarian, and pancreatic carcinomas but low expressed on the surface of peritoneal, pleural, and pericardial cells, has become an attractive target for CAR T cell therapy. Here, MSLN is linked to mesothelioma.